Asset profile
UCB7853
Biologic — subtype unspecified
Evidence outlook · lead readout
NCT04651153 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04651153: This was a randomized, quadruple-blind, placebo-controlled study, a sound design for an early safety trial that included both healthy volunteers and Parkinson's disease patients, but its only endpoints were safety-related, and results are not yet posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.